These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3429695)

  • 1. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers.
    Cheymol G; Poirier JM; Barre J; Pradalier A; Dry J
    J Clin Pharmacol; 1987 Nov; 27(11):874-9. PubMed ID: 3429695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
    Cheymol G; Poirier JM; Carrupt PA; Testa B; Weissenburger J; Levron JC; Snoeck E
    Br J Clin Pharmacol; 1997 Jun; 43(6):563-70. PubMed ID: 9205815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of propranolol and sotalol pharmacokinetics in obese subjects.
    Poirier JM; Le Jeunne C; Cheymol G; Cohen A; Barré J; Hugues FC
    J Pharm Pharmacol; 1990 May; 42(5):344-8. PubMed ID: 1976782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.
    Wójcicki J; Jaroszynska M; Droździk M; Pawlik A; Gawrońska-Szklarz B; Sterna R
    Biopharm Drug Dispos; 2003 Jul; 24(5):211-8. PubMed ID: 12784321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].
    Cheymol G
    Bull Acad Natl Med; 1990 Oct; 174(7):959-67; discussion 967-8. PubMed ID: 1981983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between nifedipine and propranolol.
    Zylber-Katz E; Turetz-Abramovitch M; Koren G; Levy M
    Fundam Clin Pharmacol; 1988; 2(1):29-35. PubMed ID: 3371839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects.
    Cheymol G; Woestenborghs R; Snoeck E; Ianucci R; Le Moing JP; Naditch L; Levron JC; Poirier JM
    Eur J Clin Pharmacol; 1997; 51(6):493-8. PubMed ID: 9112066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral activated charcoal on propranolol pharmacokinetics following intravenous administration to rabbits.
    al-Meshal MA; el-Sayed YM; al-Angary AA; al-Dardiri MM
    J Clin Pharm Ther; 1993 Feb; 18(1):39-44. PubMed ID: 8473358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.
    Cheymol G; Weissenburger J; Poirier JM; Gellee C
    Br J Clin Pharmacol; 1995 Jun; 39(6):684-7. PubMed ID: 7654489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol.
    Regårdh CG; Johnsson G; Jordö L; Lungborg P; Persson BA; Rönn O
    J Cardiovasc Pharmacol; 1980; 2(6):715-23. PubMed ID: 6160322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.
    Bowman SL; Hudson SA; Simpson G; Munro JF; Clements JA
    Br J Clin Pharmacol; 1986 May; 21(5):529-32. PubMed ID: 3718810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states.
    Jacobs G; Whittem T; Sams R; Calvert C; Ferguson D
    Am J Vet Res; 1997 Apr; 58(4):398-403. PubMed ID: 9099387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative evaluation of propranolol pharmacokinetics in obese versus ideal weight individuals: A blueprint towards a personalised medicine.
    Mortlock R; Smith V; Nesci I; Bertoldi A; Ho A; El Mekkawi Z; Kakuzada L; Williams K; Pont L; De Rubis G; Dua K
    Chem Biol Interact; 2023 Feb; 371():110351. PubMed ID: 36640929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers.
    Le Jeunne C; Poirier JM; Cheymol G; Ertzbischoff O; Engel F; Hugues FC
    Eur J Clin Pharmacol; 1991; 41(2):171-4. PubMed ID: 1683835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia.
    Wójcicki J; Sulzyc-Bielicka V; Kutrzeba J; Gawrońska-Szklarz B; Droździk M; Sterna Z
    J Clin Pharmacol; 1999 Aug; 39(8):826-33. PubMed ID: 10434235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lack of effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults.
    Panton LB; Guillen GJ; Williams L; Graves JE; Vivas C; Cediel M; Pollock ML; Garzarella L; Krumerman J; Derendorf H
    J Clin Pharmacol; 1995 Sep; 35(9):885-94. PubMed ID: 8786248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug pharmacokinetics in the obese.
    Cheymol G
    Fundam Clin Pharmacol; 1988; 2(3):239-56. PubMed ID: 3042569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and gender influence the stereoselective pharmacokinetics of propranolol.
    Gilmore DA; Gal J; Gerber JG; Nies AS
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1181-6. PubMed ID: 1602383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers.
    Vanakoski J; Seppälä T
    Eur J Clin Pharmacol; 1995; 48(2):133-7. PubMed ID: 7589027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of sufentanil in obese patients.
    Schwartz AE; Matteo RS; Ornstein E; Young WL; Myers KJ
    Anesth Analg; 1991 Dec; 73(6):790-3. PubMed ID: 1835321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.